A phase iia trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e22201-e22201
Author(s):  
Ting Bao ◽  
Andrew David Seidman ◽  
Lauren Piulson ◽  
Xi Chen ◽  
Andrew J. Vickers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients

scholarly journals Preventive Effect of Cryotherapy on Persistent Chemotherapy-induced Peripheral Neuropathy After Completion of Weekly Paclitaxel Therapy for Breast Cancer

2021 ◽  
Author(s):  
Hideo Shigematsu ◽  
Yuri Kimura ◽  
Tomoko Itagaki ◽  
Daisuke Yasui
Keyword(s):  
Breast Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Weekly Paclitaxel ◽  
Control Group ◽  
Lower Grade ◽  
Breast Cancer Patients ◽  
Preventive Effect ◽  
One Year ◽  
Paclitaxel Treatment

Abstract BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is an important adverse event of taxane-based chemotherapy, which can persist in a substantial proportion of patients for years. Cryotherapy therapy is shown to be effective in prevention of CIPN during chemotherapy, but its protective effect on persistent CIPN has not been reported. MethodsCases enrolled in a randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966) were evaluated for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score and Patient Neurotoxicity Questionnaire (PNQ) at more than one year after completion of weekly paclitaxel. ResultsThirty-eight cases were evaluated for persistent CIPN with a median 2.3 (1.3-3.1) years after completion of weekly paclitaxel. The incidence of a significant decrease in FACT-NTX scores was numerically lower in the cryotherapy group compared with the control group (15.8% vs. 36.8%, p = 0.13). There was also a lower grade of PNQ sensory (p = 0.02) and motor (p = 0.17) in the cryotherapy group compared with the control group. ConclusionIn breast cancer patients treated with weekly paclitaxel, cryotherapy resulted in a numerical decrease in the incidence of persistent CIPN at more than one year after completion of weekly paclitaxel treatment.

scholarly journals Preventive effect of cryotherapy on persistent chemotherapy-induced peripheral neuropathy after completion of weekly paclitaxel therapy for breast cancer

2021 ◽  
Author(s):  
Hideo Shigematsu ◽  
Yuri Kimura ◽  
Tomoko Itagaki ◽  
Daisuke Yasui
Keyword(s):  
Breast Cancer ◽  
Peripheral Neuropathy ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Weekly Paclitaxel ◽  
Control Group ◽  
Lower Grade ◽  
Breast Cancer Patients ◽  
Preventive Effect ◽  
One Year

Abstract BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is an important adverse event of taxane-based chemotherapy, which can persist in a substantial proportion of patients for years. Cryotherapy therapy is shown to be effective in prevention of CIPN during chemotherapy, but its protective effect on persistent CIPN has not been reported. MethodsThis observational study was performed as an ancillary analysis of a randomized trial investigating the preventive effect of cryotherapy on weekly paclitaxel-induced CIPN in breast cancer patients (UMIN000034966). Eligible cases were evaluated for Functional Assessment of Cancer Therapy-Neurotoxicity (FACT-NTX) score and Patient Neurotoxicity Questionnaire (PNQ) at more than one year after completion of weekly paclitaxel. ResultsThirty-eight cases were evaluated for persistent CIPN with a median 2.3 (1.3-3.1) years after completion of weekly paclitaxel. The incidence of a significant decrease in FACT-NTX scores was numerically lower in the cryotherapy group compared with the control group (15.8% vs. 36.8%, p = 0.13). There was also a lower grade of PNQ sensory (p = 0.02) and motor (p = 0.17) in the cryotherapy group compared with the control group. ConclusionIn breast cancer patients treated with weekly paclitaxel, cryotherapy resulted in a numerical decrease in the incidence of persistent CIPN after completion of weekly paclitaxel therapy.

Taxane-induced peripheral neuropathy and quality of life in breast cancer patients

2020 ◽  
Vol 26 (6) ◽  
pp. 1421-1428
Author(s):  
Ebrahim Salehifar ◽  
Ghasem Janbabaei ◽  
Abbas Alipour ◽  
Nasim Tabrizi ◽  
Razieh Avan
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Health Status ◽  
Peripheral Neuropathy ◽  
Global Health ◽  
Cancer Patients ◽  
Physical Functioning ◽  
Role Functioning ◽  
Breast Cancer Patients

Purpose Taxane-induced peripheral neuropathy (TIPN) is a common and bothersome toxicity. This study aimed to determine the incidence and severity of TIPN in patients with breast cancer and to investigate the relationship between TIPN and quality of life. Methods A total of 82 breast cancer patients with TIPN symptoms were included in this study. The criteria of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03) and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30, version 3.0) were used to evaluate grading of sensory neuropathy and quality of life, respectively. Analysis of the data was done by IBM SPSS statistics version 23. Results A total of 346 patients received taxane-based chemotherapy and 82 patients (23.7%) experience TIPN. The mean (SD) global health status/quality of life, physical functioning, role functioning, and pain subscales were 60.63 (5.26), 80.64 (9.05), 81.77 (10.41), and 43.88 (11.27), respectively. There were significant negative correlations between global health status/quality of life, physical functioning, and role functioning subscales with the grade of neuropathy (r = −0.33, −0.80, and −0.61, respectively) and positive correlation between pain subscale and the grade of neuropathy (r = 0.70). Conclusion This study shows a clear association between TIPN and worsened quality of life. These findings emphasize on detecting and management of TIPN in an effort to improve the quality of life of breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document